Back to Immuno-Oncology Scientific Updates Webcast 3: Tumor Mutational Burden
ASCP Scientific Updates are a quarterly series of 30-minute on-demand webcasts containing up-to-the-minute information on various therapeutic agents, disease states, and thresholds that impact immuno-oncology diagnostics in solid tumors and hematologic malignancies.
This webcast provides an overview of tumor mutational burden (TMB).
This webcast will provide participants with a basic understanding of tumor mutational burden. You’ll learn what TMB is, TMB across different tumor types, and the types of mutational signatures that can be associated with high TMB. You will also learn the evidence for TMB as a biomarker in immuno-oncology, as well as the methods for TMB determination.
As a result of participating in this course, learners will be able to:
• Describe what tumor mutational burden is
• Discuss the evidence for TMB as a biomarker in immuno-oncology
• Describe the methods for TMB determination
Lauren Ritterhouse, MD, PhD
Co-Director, Molecular Diagnostics and Clinical Genomics Laboratories
Division of Genomic and Molecular Pathology
The University of Chicago
Credit Designation Statement
The ASCP designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
These activities also meet MOC Part II Lifelong Learning and Self-Assessment Module (SAMs CME) requirements.
ASCP designates these live activities for a maximum of 0.5 CMLE credit. These activities meet CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line.
Funded by an independent educational grant from AstraZeneca.